MeiraGTx Holdings (FRA:328) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:328 MeiraGTx Holdings PLC FRA:328
59 GF Score
Price €11.40
GF Value €87.36
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MeiraGTx Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

MeiraGTx Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €2.0 Mil. MeiraGTx Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €96.2 Mil. MeiraGTx Holdings's annualized EBITDA for the quarter that ended in Jun. 2026 was €582.6 Mil. MeiraGTx Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MeiraGTx Holdings's Debt-to-EBITDA or its related term are showing as below:

FRA:328' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.56   Med: -0.44   Max: 1.06
Current: 1.06

During the past 10 years, the highest Debt-to-EBITDA Ratio of MeiraGTx Holdings was 1.06. The lowest was -1.56. And the median was -0.44.

FRA:328's Debt-to-EBITDA is ranked better than
53.29% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs FRA:328: 1.06

MeiraGTx Holdings  (FRA:328) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

MeiraGTx Holdings Debt-to-EBITDA Related Terms

MeiraGTx Holdings Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for MeiraGTx Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MeiraGTx Holdings Debt-to-EBITDA Chart

MeiraGTx Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MeiraGTx Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:328 vs JBIO, VOR, OMER: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, MeiraGTx Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MeiraGTx Holdings Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MeiraGTx Holdings's Debt-to-EBITDA falls into.


FRA:328
59GF Score
MeiraGTx Holdings PLC FRA:328
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MeiraGTx Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MeiraGTx Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(23.446719741155 + 52.066073481204) / -79.269668482499
=-0.95

MeiraGTx Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.0117204583224 + 96.231085454386) / 582.64932000736
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is MeiraGTx Holdings (FRA:328) Overvalued in 2026?

Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued. The current stock price of €11.40 is trading 87% below its estimated GF Value™ of €87.36. GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.

Key valuation signals for FRA:328:

  • Debt-to-EBITDA:
  • GF Value™: €87.36 vs. price of €11.40 (87% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the FRA:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MeiraGTx Holdings Business Description

Other Exchanges MGTX:USA328:Germany
Address 655 Third Avenue, Suite 1115, New York, NY, USA, 10017
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
59GF Score

Get the complete analysis for FRA:328

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.40
Price
€87.36
GF Value